This review describes the role of CD38 in the development of NAFLD in terms of Macrophage-1, insulin resistance, and abnormal lipid accumulation in order to offer recommendations for future NAFLD pharmacological trials. This evidence concerns the gene CD38 and metabolic dysfunction-associated steatotic liver disease.